Evive Biotech is a global biologics company focused on oncology and inflammatory disorders. We are developing a portfolio of novel therapies to deliver life-saving treatments for patients worldwide.
We develop revolutionary remedies for a healthy, happy world.
We strive to enable access to treatment options for patients for whom no effective standard of care exists. We aim to be one of the first Asian biologics companies to advance a novel biologic product from pre-clinical studies to BLA submission and commercial launch, and we are developing a portfolio of novel solutions to treat serious diseases for patients worldwide.
Exploring new frontiers of innovation and treatments
Striving to improve and drive bold initiatives to deliver best outcomes for patients
Working together to address needs of patients, physicians and customers
Improving the standard of care for patients through our pursuit of innovative biological therapies
Building trust with employees and partners through transparency, consistency, and reliability
What’s Going On
Our innovative assets have recently achieved significant milestones, including the completion of global Phase III clinical trials and the receipt of orphan drug designation. We are engaging with potential partners and the broader scientific community to share our successes and to ensure broad access to treatment options for patients.
Evive Biotech and Dr. Xiao Qiang Yan Form Joint Venture to Further Develop Bi-specific Antibody Platform ITab
Evive Biotech Announces First Patient Dosed in Phase 2 Study to Evaluate the Efficacy and Safety of F-652 in Patients with Moderate to Severe COVID-19
Mucosal Immunology Article Details IL-22’s Critical Role in Maturation of Certain Epithelial Cells
Evive Biotech Meets Primary and Secondary Endpoints in Global Phase III Clinical Trial for Their Novel Chemotherapy-induced Neutropenia Treatment
Evive Successfully Concludes China Phase III Clinical Trial of F-627 for Chemotherapy-induced Neutropenia
Evive Receives Orphan-Drug Designation from the U.S. FDA for F-652 for the Treatment of Acute Graft vs Host Disease